PMID-sentid	Pub_year	Sent_text		comp_official_name	comp_offsetprotein_name	organism	prot_offset
11050699-0	2000	Pharmacodynamic study of low molecular weight dermatan sulphate (Desmin) after a single subcutaneous administration in patients with renal insufficiency.	Dermatan Sulfate	46-63	desmin	Homo sapiens	65-71	
9352383-0	1997	Bioavailability of Desmin, a low molecular weight dermatan sulfate, after subcutaneous administration to healthy volunteers.	Dermatan Sulfate	50-66	desmin	Homo sapiens	19-25	
9684733-0	1998	Pharmacokinetics of low molecular weight dermatan sulphate (desmin) in different cohorts of patients.	Dermatan Sulfate	41-58	desmin	Homo sapiens	60-66	
9626917-0	1998	Desmin (a low molecular weight dermatan sulphate) versus heparin in the treatment of patients with deep venous thrombosis.	Dermatan Sulfate	31-48	desmin	Homo sapiens	0-6	
9626917-1	1998	OBJECTIVE: There is theoretical and experimental evidence which indicates that Desmin, a low molecular weight dermatan sulphate, could be an attractive alternative to heparin in the treatment of deep venous thrombosis (DVT).	Dermatan Sulfate	110-127	desmin	Homo sapiens	79-85	
9100165-2	1997	Ten patients affected by proximal deep venous thrombosis were treated in an open study with a low-molecular-weight dermatan sulphate (Desmin), administered at doses of 400 mg (intravenous bolus) followed by 1200 mg/day infused intravenously for 10 days, without activated partial thromboplastin adjustment.	Dermatan Sulfate	115-132	desmin	Homo sapiens	134-140	
9352383-1	1997	The bioavailability of two different s.c. doses of Desmin (a new low molecular weight dermatan sulfate) was evaluated in 12 healthy volunteers (6 men, 6 women aged 22-45 years) who were injected, on 3 separate days and with a wash-out period of at least 21 days between each administration, with 200 and 300 mg of Desmin by the s.c. route and 200 mg by the i.v.	Dermatan Sulfate	86-102	desmin	Homo sapiens	51-57	
8837309-0	1996	Pharmacology of a new low molecular weight dermatan sulphate (Desmin) in healthy volunteers: repeated daily intramuscular administration of 400 mg for a week.	Dermatan Sulfate	43-60	desmin	Homo sapiens	62-68	
8815578-2	1996	However, the low molecular weight (LMW) dermatan sulphate Desmin 370 has been shown to generate circulating anti-Xa activity following administration to humans.	Dermatan Sulfate	40-57	desmin	Homo sapiens	58-64	
7824960-0	1994	Pharmacological activity of a low molecular weight dermatan sulfate (desmin) in healthy volunteers.	Dermatan Sulfate	51-67	desmin	Homo sapiens	69-75	
8810655-2	1996	Patients were randomly allocated to three treatment groups to receive a new low-molecular-weight dermatan sulfate (Desmin) at the dose, respectively, of 100 mg once daily by subcutaneous (SC) route, 100 mg twice a day SC, and 200 mg once daily by intramuscular (IM) route.	Dermatan Sulfate	97-113	desmin	Homo sapiens	115-121	
8845462-1	1996	Low-molecular-weight (LMW)-dermatan sulfate (Desmin) with the mean molecular weight of 5600 Da has been obtained by limited depolymerization of natural dermatan sulfate.	Dermatan Sulfate	27-43	desmin	Homo sapiens	45-51	
8845462-1	1996	Low-molecular-weight (LMW)-dermatan sulfate (Desmin) with the mean molecular weight of 5600 Da has been obtained by limited depolymerization of natural dermatan sulfate.	Dermatan Sulfate	152-168	desmin	Homo sapiens	45-51	
8533121-0	1995	Pharmacology of desmin (low molecular weight dermatan sulphate) in healthy volunteers following intravenous bolus administration of different dosages (200, 400, 800 mg).	Dermatan Sulfate	45-62	desmin	Homo sapiens	16-22	
8533121-1	1995	Eight healthy volunteers (6 males, 2 females, mean age 31.6 yrs), were administered--on three separate days--200, 400 and 800 mg of a new low molecular weight Dermatan sulphate (Desmin), given as a single i.v.	Dermatan Sulfate	159-176	desmin	Homo sapiens	178-184